Unique ID issued by UMIN | UMIN000028630 |
---|---|
Receipt number | R000032765 |
Scientific Title | A Phase I/II trial of focal carbon-ion radiotherapy using 4 fractions for the patients with local recurrence prostate cancer after radiotherapy |
Date of disclosure of the study information | 2017/08/29 |
Last modified on | 2023/08/14 09:42:03 |
A Phase I/II trial of focal carbon-ion radiotherapy using 4 fractions for the patients with local recurrence prostate cancer after radiotherapy
Carbon-ion radiotherapy for local recurrence prostate cancer
A Phase I/II trial of focal carbon-ion radiotherapy using 4 fractions for the patients with local recurrence prostate cancer after radiotherapy
Carbon-ion radiotherapy for local recurrence prostate cancer
Japan |
Prostate cancer
Urology | Radiology |
Malignancy
NO
To evaluate the safety and efficacy of focal carbon-ion radiotherapy using 4 fractions for the patients with local recurrence prostate cancer after radiotherapy
Safety
Exploratory
Pragmatic
Phase I,II
Acute and late adverse effect
Biochemical relapse free survival, overall survival, Clinical relapse free survival, cancer specific survival, dose-volume evaluation, QOL evaluation
Interventional
Single arm
Non-randomized
Open -no one is blinded
Uncontrolled
1
Treatment
Device,equipment |
Carbon-ion radiotherapy of 40Gy(RBE)in 4 fraction within 1 week.
Not applicable |
Not applicable |
Male
1) Local recurrence biopsy proven prostate cancer after radical radiotherapy.
2) rT2a-T2bN0M0 according to MRI, CT and bone scintigram (visible lesion in MRI).
3) PSA < 8.0 ng/ml before biopsy proven local recurrence after biochemical relapse.
4) PSA doubling time > 6 months.
5) Teststeron value within 30 days before starting this treatment > within normal lower limit.
6) Performance Status (ECOG) of 0-1.
7) Approved by document.
1) Other salvage therapy has been performed except for the case with positive local recurrence by biopsy after discontinuance of hormonal therapy
2) Presence of biopsy proven separate lesions except for visible lesion in MRI.
3) Having at least one factor of GS>9, T3b and PSA > 40 ng/ml before initial radical radiotherapy.
4) occuring Grade 3 or more severe adverse effect after initial radical radiotherapy.
5) Ineligible dose constraint of risk organs
6) Considered to be castration resistant prostate cancer
7) Presence of active double cancer
20
1st name | Hiroshi |
Middle name | |
Last name | Tsuji |
QST Hospital, National Institutes for Quantum Science and Technology
Treatment division
263-8555
4-9-1 Anagawa, Inage Ward, Chiba City
043-251-2111
tsuji.hiroshi@qst.go.jp
1st name | Goro |
Middle name | |
Last name | Kasuya |
QST Hospital, National Institutes for Quantum Science and Technology
Treatment division
263-8555
4-9-1 Anagawa, Inage Ward, Chiba City
043-251-2111
kasuya.goro@qst.go.jp
QST Hospital, National Institutes for Quantum Science and Technology
Treatment division
Ministry of Education
National Institutes for Quantum Science and Technology
Government offices of other countries
National Institutes for Quantum Science and Technology Certified Review Board
4-9-1 Anag awa, Inag e-ku, Chiba-shi, Chiba
0 4 3 -2 0 6 -4 7 0 6
helsinki@qst.go.jp
NO
国立研究開発法人量子科学技術研究開発機構 QST病院
2017 | Year | 08 | Month | 29 | Day |
Unpublished
Terminated
2017 | Year | 08 | Month | 09 | Day |
2019 | Year | 07 | Month | 31 | Day |
2017 | Year | 08 | Month | 24 | Day |
2025 | Year | 08 | Month | 31 | Day |
2017 | Year | 08 | Month | 10 | Day |
2023 | Year | 08 | Month | 14 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000032765
Research Plan | |
---|---|
Registered date | File name |
Research case data specifications | |
---|---|
Registered date | File name |
Research case data | |
---|---|
Registered date | File name |